{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:47:09Z","timestamp":1791982029832,"version":"4.4.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.aohep.2026.102449","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:27:07Z","timestamp":1790436427000},"page":"102449","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["EP547 (MRGPRX4 inverse agonist) for cholestatic pruritus due to primary biliary cholangitis or primary sclerosing cholangitis: Results from the phase 2 randomized, placebo-controlled PACIFIC study"],"prefix":"10.1016","author":[{"given":"Cynthia","family":"Levy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gideon M.","family":"Hirschfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"Dehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hemming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Weyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6855-8268","authenticated-orcid":false,"given":"Nan","family":"Nan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9263-948X","authenticated-orcid":false,"given":"Andreas E.","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.aohep.2026.102449_bib0001","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1159\/000446057","article-title":"Cholestatic itch management","volume":"50","author":"Mittal","year":"2016","journal-title":"Curr Probl Dermatol"},{"issue":"1","key":"10.1016\/j.aohep.2026.102449_bib0002","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.immuni.2023.12.012","article-title":"The MRGPR family of receptors in immunity","volume":"57","author":"Gour","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.aohep.2026.102449_bib0003","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.48431","article-title":"MRGPRX4 is a bile acid receptor for human cholestatic itch","volume":"8","author":"Yu","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.aohep.2026.102449_bib0004","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1750-1172-9-89","article-title":"Intractable itch relieved by 4-phenylbutyrate therapy in patients with progressive familial intrahepatic cholestasis type 1","volume":"9","author":"Hasegawa","year":"2014","journal-title":"Orphanet J Rare Dis"},{"issue":"S1","key":"10.1016\/j.aohep.2026.102449_bib0005","first-page":"757A","article-title":"Development of EP547: a potent, highly selective MRGPRX4 inverse agonist for the treatment of cholestatic and uremic pruritus","volume":"74","author":"Yeager","year":"2021","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.aohep.2026.102449_bib0006","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.3748\/wjg.v21.i5.1404","article-title":"Jaundice associated pruritis: a review of pathophysiology and treatment","volume":"21","author":"Bassari","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.aohep.2026.102449_bib0007","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/hep.32771","article-title":"AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma","volume":"77","author":"Bowlus","year":"2023","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.aohep.2026.102449_bib0008","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2026.102449_bib0009","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.44116","article-title":"Identification of a bilirubin receptor that may mediate a component of cholestatic itch","volume":"8","author":"Meixiong","year":"2019","journal-title":"Elife"},{"issue":"6","key":"10.1016\/j.aohep.2026.102449_bib0010","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1007\/s10620-023-07862-z","article-title":"Cholestatic pruritus treatments in primary biliary cholangitis and primary sclerosing cholangitis: a systematic literature review","volume":"68","author":"Smith","year":"2023","journal-title":"Dig Dis Sci"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268126002693?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268126002693?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:00:15Z","timestamp":1791979215000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268126002693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":10,"alternative-id":["S1665268126002693"],"URL":"https:\/\/doi.org\/10.1016\/j.aohep.2026.102449","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EP547 (MRGPRX4 inverse agonist) for cholestatic pruritus due to primary biliary cholangitis or primary sclerosing cholangitis: Results from the phase 2 randomized, placebo-controlled PACIFIC study","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aohep.2026.102449","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s) and Incyte Corporation. Published by Elsevier Espa\u00f1a, S.L.U on behalf of Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C..","name":"copyright","label":"Copyright"}],"article-number":"102449"}}